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Increasing evidence has accumulated for an involvement
of the inactivation of tumour suppressor genes at
chromosome 10q in the carcinogenesis of brain tumours,
melanomas, and carcinomas of the lung, the prostate, the
pancreas, and the endometrium. The gene DMBT1
(Deleted in Malignant Brain Tumours 1) is located at
chromosome 10q25.3 – q26.1, within one of the putative
intervals for tumour suppressor genes. DMBT1 is a
member of the scavenger-receptor cysteine-rich (SRCR)
superfamily and displays homozygous deletions or lack
of expression in glioblastoma multiforme, medulloblas-
toma, and in gastrointestinal and lung cancers. Based on
these properties, DMBT1 has been proposed to be a
candidate tumour suppressor gene. We have determined
the genomic sequence of DMBT1 to allow analyses of
mutations. The gene has at least 54 exons that span a
genomic region of about 80 kb. We have identified a
putative exon with coding potential for a transmembrane
domain. Our data further suggest that alternative
splicing gives rise to isoforms of DMBT1 with a
dierential utilization of SRCR domains and SRCR
interspersed domains. The major part of the gene
harbours locus specific repeats. These repeats may point
to the DMBT1 locus as a region susceptible to
chromosomal instability.
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Introduction
A variety of human tumours displays losses of
heterozygosity (LOHs) at the long arm of chromo-
some 10 (10q). In particular, 10q losses have been
observed in 60 – 95% of the glioblastoma multiformes
(GBMs), as well as in a substantial fraction of
melanomas and carcinomas of the pancreas, the
prostate, the lung and the endometrium (Louis and
Gusella, 1995; Rasheed et al., 1995; Albarosa et al.,
1996; Healy et al., 1996; Hahn et al., 1995; Komiya et
al., 1996; Kim et al., 1998; Nagase et al., 1996). Several
distinct loci for potential tumour suppressor genes have
been identified based on studies of microsatellite
markers along chromosome 10q (Komiya et al., 1996;
Kim et al., 1998; Nagase et al., 1996). The gene
MMAC1/PTEN has been identified as the tumour
suppressor gene for the 10q23.3 region (Steck et al.,
1997; Li et al., 1997) and has been demonstrated to
harbour deletions and mutations in about 20% of the
tumours with LOH at 10q (Teng et al., 1997). The
further refinement of the LOH pattern at chromo-
some 10q in prostate, endometrial, and small cell lung
cancer (SCLC) has indicated that at least three
additional tumour suppressor loci may be present
telomeric to the MMAC1/PTEN locus. One of these
loci overlaps between the three cancer types in the
D10S209 –D10S587 region at chromosome 10q25.3 –
q26.1 (Komiya et al., 1996; Kim et al., 1998; Nagase et
al., 1996).
By representational dierence analysis, we have
identified a gene of the scavenger-receptor cysteine-
rich (SRCR) superfamily within this interval (Mol-
lenhauer et al., 1997). The gene has been designated as
Deleted in Malignant Brain Tumours 1 (DMBT1), due
to the presence of homozygous deletions in medullo-
blastoma and GBM. Based on the chromosomal
localization and on the finding, that tumours display
homozygous deletions or lack the expression, DMBT1
has been proposed as a candidate tumour suppressor
gene for brain, gastrointestinal, and lung tumours
(Mollenhauer et al., 1997, Somerville et al., 1998;
Mori et al., 1999; Wu et al., 1999). However, due to
the lack of information about the exon – intron
structure, it neither has been possible to elaborate
which parts of the gene are concerned by the
deletions, nor a systematic screening for mutations
has been feasible. We now report the genomic
sequence and the organization of the DMBT1 gene.
Our data indicate that alternatively spliced forms of
DMBT1 exist, that may also include variants that act
as transmembrane receptors. The DMBT1 locus
further contains multiple locus specific repeats that
may particularly be susceptible to genomic instability.
Results
Genomic structure of the DMBT1 gene
The initial characterization of the 6 kb transcript of
DMBT1 from human foetal lung has shown that the
SRCR domains and the SRCR interspersed domains
(SIDs) are highly homologous to each other
(Mollenhauer et al., 1997). Therefore, a rapid
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determination of the exon – intron boundaries by the
use of sequencing primers located inside the coding
sequences was largely excluded. Attempts aiming at a
refined restriction mapping of the genomic PAC and
Lambda clones that cover the genomic locus suggested
that also intronic sequences share substantial homo-
logies (not shown). During the process of sequencing,
the clones PG141BF17 and HLPS41 that have been
considered to overlap in our initial map (Mollenhauer
et al., 1997) turned out to be misaligned due to the
high homology of the non-coding sequences. The
subclone PG141BF17 further harboured an interstitial
deletion of about 8 kb. The gaps were closed by
clones isolated from a repeated screen of the genomic
human Lambda PS library (see Materials and methods
section).
In total, 103 kb were sequenced including 79 kb
harbouring the exons, as well as about 13 kb of the 5’
region and 11 kb of the 3’ region of the gene,
respectively. The sequence is available under EMBL
Accession no. AJ243211 and a schematical presenta-
tion of the genomic DMBT1 locus is shown in Figure
1. The RsaI band pattern was found to be informative
for the verification of the assembly by Southern blot
hybridization. Using a cDNA sequence that contains
the nucleotide sequence of SRCR1 to SID2 (DMBT1/
sr1sid2) and the intronic sequence DMBT1/59m21 as
probes for the hybridization with genomic DNA from
a set of normal individuals, we observed the pattern
that was predicted by the MAPSORT program of the
GCG package (Figures 1a and 2a,b).
The polymorphic marker D10S1421 (EMBL Acces-
sion no. HS291187) could be located 5 kb upstream of
the first exon of DMBT1 (Figure 1b) by database
searches with the 5’ genomic sequence.
The exon – intron boundaries (Figure 1c and Table
1) were identified by comparison of the genomic
sequence with the cDNA sequence of the 6 kb
transcript (EMBL Accession no. AJ000342). In addi-
tion to the exons contained within the 6 kb transcript,
Figure 1 Genomic structure of the DMBT1 gene. All drawings are brought to scale to each other. (a) Scale in kilobases followed
by the recognition sites for the restriction enzymes BglII and RsaI. Sizes of the RsaI fragments with potential match to the probes
DMBT1/sr1sid2 and DMBT1/59m21 are given in kb on top and at the bottom of the RsaI line, respectively. The bottom line depicts
the potential hybridization sites of the intronic probe DMBT1/59m21 in the genomic sequence with the per cent match of the probe
to the respective RsaI fragment below. (b) Top line: positions of the STSs in the genomic sequence. STSs that previously had been
used for deletion analyses and/or for mapping are indicated as red boxes, the polymorphic tetranucleotide repeat D10S1421 as a
green box. The diagram in the centre position summarizes the results that had been obtained from the deletion analyses of the STSs
in brain tumours (Mollenhauer et al., 1997; Somerville et al., 1998). The percentage of tumours with a homozygous deletion in the
respective STS is followed by the cases with homozygous deletions per cases analysed in brackets. Bottom line: distribution of the
three types of locus specific repeats (DMBT1reps) in the genomic sequence. Type 1 repeats are drawn as blue boxes, type 2 repeats
as yellow, orange, red or brown boxes. Equal colouring indicates aliation to one subclass as defined by the crosswise comparison
of the repeating units (see also Figure 4 and text). Type 3 repeats are indicated as bars on top of the line. (c) Top line: exon-intron
structure drawn in scale to (a) and (b). Only every second exon is numbered. The exons are coloured according to the domains that
they are coding for. The domains are depicted in the schematical drawings of the domain organizations below. The putative
transmembrane domain exon is indicated as a black box. The bottom three lines show, from top to bottom, the prospective domain
structure of the proteins that are encoded by the sequence assembled from the genomic exons (Prototype), the 8 kb transcript
assembled from RT–PCR products from human adult lung (DMBT1/8 kb.1), and the formerly characterized 6 kb transcript
(DMBT1/6 kb.1; Mollenhauer et al., 1997; EMBL Accession no. AJ000342), respectively. Pink triangle: leader peptide; blue square:
unknown motif; red circles: scavenger-receptor cysteine-rich (SRCR) domains; orange circle without specification: SRCR
interspersed domains (SIDs); TTT: threonine rich sequence; STP: serine, threonine, proline rich stretch; violet boxes: CUB domains;
green circle: ZP domain; EHD: stretch with homology to rat Ebnerin (Ebnerin homologous domain)
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14 further putative exons with coding potential for
SRCR domains and SIDs were identified by virtue of
their homology. In total, exons for 13 SRCR
domains and 11.5 SIDs are present in the 5’ part
of the gene (Figure 1c). In order to introduce a
generally applicable nomenclature, the SRCR do-
mains have been numbered according to the order of
their exons in the genomic sequence and the SIDs
Table 1 Summary of the exon – intron data of the DMBT1 gene
Exons are numbered according to their occurence in the genomic DNA (column 1). Column 2 and 3 depict the exon lengths and the positions in
the genomic DNA, respectively, followed by the domains encoded by the exons in column 4. Domains encoded by more than one exon are
subdivided in parts a, b and c, e.g. SID3a and SID3b. The lengths of the subsequent introns are shown in the last column. The columns with the
exon-intron boundaries contain 30 bp of the flanking intronic sequence (bold italics) and 5 bp exon sequence (normal letters). Exceptions are in
exon 1 where the nucleotides preceding the 5’-utr, as defined by the previous 5’-RACE experiments (Mollenhauer et al., 1997), are indicated as
underlined italics, and for exons 54 and 55 where the bold italics indicate the end of the 3’-utrs. Potential polyadenylation signals are bold and
underlined
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have been numbered according to the preceding
SRCR domain. Each SRCR domain is encoded by
a single exon of 321 – 324 bp in length. The first 12
SRCR encoding exons are each followed by two very
small exons of 30 bp and 33 – 42 bp in length,
respectively, that encode the subsequent SID. The
only exception is exon 16 (SRCR4) after which the
exon coding for the amino-terminal part of the
following SID is absent. We will refer to the
amino-terminal parts of the SIDs encoded by the
30 bp exons as SIDa and to the carboxy-terminal
parts as SIDb. The data obtained from the analysis
of the exon-intron structure are summarized in
Exons are numbered according to their occurence in
the genomic DNA (column 1) Table 1.
Overall, 54 exons were identified that, if continously
assembled, would give rise to a hypothetical transcript
of 7725 bp with an open reading frame of 7278 bp.
Translation of this open reading frame results in a
protein of 2426 amino acids. The putative domain
organization of this prototype is schematically depicted
in Figure 1c.
Identification of an exon with coding potential for a
transmembrane domain
The two SRCR proteins mouse CRP-ductin and rat
Ebnerin show a similar domain organization compared
to DMBT1, with repeated SRCR domains in the N-
terminal parts and CUB-domains and a ZP-domain in
the C-terminal parts of the proteins. Both molecules
exist as a soluble extracellular variant and as an
isoform that is a transmembrane molecule (Cheng et
al., 1996; Li and Snyder, 1995). We used the cDNA
sequences encoding the transmembrane domains
(TMDs) of these two related SRCR proteins to search
Figure 2 Verification of the sequence assembly by Southern blot
hybridization. (a) RsaI band pattern in normal individuals (lanes
N1 –N4) after hybridization with cDNA probe DMBT1/sr1sid2.
Due to the high homology every of the first 13 SRCR domain
encoding exons hybridizes with the probe. The SRCR domains
localizing on the respective RsaI fragment and the sizes of the
fragments in kb are indicated at the left. Twofold intensities are
observed for the 4.1 kb fragment (represented twice) and for the
3.9 kb fragment (contains 2 SRCR exons). Fainter bands at 1.6,
1.2 and 1.1 kb result from hybridization of the short SID exons.
(b) RsaI band pattern in normal individuals (lanes N5–N8) after
hybridization with the intronic probe DMBT1/59m21. The
fragment sizes in kb are indicated at the left. Note that all
sequences below an 86% homology do not hybridize (0.9 and
0.4 kb fragment in Figure 1a) unless they are represented twice
(the two 1.6 kb fragments with 74 and 71% homology,
respectively; see Figure 1a)
Figure 3 Amino acid sequence alignments. (a) Alignment of the translated putative DMBT1 exon 55 (TMD DMBT1) to the
carboxy-termini of the transmembrane isoforms of rat Ebnerin and mouse CRP-ductin. The three sequences terminate with an in
frame stop codon behind the last amino acid (not shown). Transmembrane domains in Ebnerin and CRP ductin, as suggested by Li
and Snyder (1995), and Cheng et al. (1996), respectively, are underlined. The underlined hydrophobic 19 amino acid motif in the
DMBT1 sequence is the potential TMD. Asterisks: identical amino acids; points: similar amino acids. (b) Alignment of the 13
amino-terminal SRCR domains of DMBT1. The sequences have been translated from the genomic exons. Potential sites for N-
linked glycosylation are indicated as red boxes. Dierences between the domains are marked with yellow boxes. Mixed boxes
indicate amino acid dierences that lead to the formation of a new potential N-glycosylation site. (c) Alignment of the SIDs that
have been translated from the exons in the genomic sequence. The SIDs subdivide, based on their homology, in two classes (left and
right panel, respectively). Amino acid dierences between the domains are marked as yellow boxes
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for a corresponding stretch in the DMBT1 genomic
sequence. A nucleotide sequence with 69 and 73%
homology to the CRP-ductin and Ebnerin cDNA
sequences, respectively, was identified 1.4 kb down-
stream of exon 54, the exon coding for the last part of
the ZP-domain and containing the 3’-utr (Figure 1c).
The putative exon 55 contains a splice acceptor site at
its 5’ end that matches the consensus (Table 1). An
alignment of the translated sequence reveals a
similarity of 67% to the CRP-ductin and Ebnerin
amino acid sequences (Figure 3a). The hydrophobicity
plot of the translated hypothetical exon 55 reveals a
stretch of 19 hydrophobic amino acids that is
compatible with a TMD. The stop codon would be
located in an equivalent position as in the two related
proteins so that a similar short cytoplasmic tail for
DMBT1 would result. Similarities are also found in the
3’-utrs, suggesting that the prospective end of exon 55,
preceded by a polyadenylation site (AATAAA), is
located 903 bp downstream of the splice site (Table 1).
Dierential utilization of SRCR domains and SIDs gives
rise to dierent DMBT1 isoforms
In our initial characterization of DMBT1, we have
noted a remarkable homology of the SRCR domains
and SIDs, respectively (Mollenhauer et al., 1997). This
finding is still consistent when also the newly identified
domains are included in the analysis. A multiple
sequence alignment demonstrated that the SRCR
domains share 87 – 100% identity at the protein level
(Figure 3b). Similar levels of homology were found for
the SIDs, with SID9 and SID10, for example, being
identical (Figure 3c).
A comparison between the 6 kb transcript and the
prototype sequence assembled from the genomic exons
allowed to determine the exon utilization in the 5’ part
of the transcript. The 6 kb transcript unambiguously
lacks the exons 15 (carboxy-terminal half of SID3) to
24 (SRCR7). However, in this region, either exon 14 or
exon 25 is utilized to give rise to the amino-terminal
part of the SID that is located between SRCR3 and
SRCR8 (Figure 1c). These two possibilites are
indistinguishable from each other because of the
identity of exons 14 (SID3a) and 25 (SID7a).
Similarily, the exon utilization in the more 3’ region,
where one SRCR domain and one SID is missing in
the 6 kb transcript, could not be determined in detail,
because of the identity of SID9/SRCR10 and SID10/
SRCR11 both at the protein and at the nucleotide level
(Figure 3b,c, and data not shown).
Taken together, these comparisons and the results
obtained from the initial characterization of DMBT1 by
Northern blot analyses and RT –PCR (Mollenhauer et
al., 1997) strongly suggested that alternative splicing may
give rise to isoforms of the DMBT1 protein that dier in
the utilization of SRCR domains and SIDs. To further
confirm this, we sequenced one of the RT –PCR
products that has been obtained for the centre part of
the transcript from adult lung and assembled the 8 kb
transcript from the overlapping RACE- and long range
RT –PCR products (Mollenhauer et al., 1997; EMBL
Accession no. AJ243224). The assembled cDNA com-
prises 7656 bp with an open reading frame of 7209 bp.
The exon utilization in this transcript was identical to the
one proposed for the prototype cDNA, except that
exons 14 and 17 (SID3a and SID4b) were absent (Figure
1c). Since it is not yet known whether splice variants exist
that give rise to transcripts of similar size but with
dierent exon utilization, we will refer to the two
transcripts that have been characterized so far as
DMBT1 6 kb variant 1 (DMBT1/6 kb.1) and DMBT1
8 kb variant 1 (DMBT1/8 kb.1), respectively.
The homozygous deletions cluster in the region
containing the exons coding for the SRCR domains and
SIDs
Summarizing the data obtained from the analysis of
the DMBT1 specific sequence tagged sites (STSs) in
brain tumours (Mollenhauer et al., 1997; Somerville et
al., 1998) suggests the presence of two potential hot
spots for deletions. The first one is located around the
STS 74k that displayed homozygous deletions in 4/21
(19%) of the GBM (Figure 1b). The 3’ borderline of
this STS is located 22 bp upstream of the 5’-utr of
DMBT1, so that at least parts of the promotor and
probably the exon with the ATG start codon would
be removed by the deletion. The second hot spot
apparently localizes in the region around the closely
neighboured STSs G14ext and G14 that are deleted in
13/49 (27%) of the brain tumours (Figure 1b), in 7/58
(12%) of the oesophageal tumours (Mori et al., 1999),
and in 4/40 (10%) of the small cell lung cancers (Wu
et al., 1999). Taken together, of the 18 brain tumours
with deletions in DMBT1, nine tumours (50%)
showed a loss only of the STSs G14ext/G14 and
another two tumours display a co-involvement of
these STSs (GBMs G2 in Mollenhauer et al., 1997
and CCF 4 in Somerville et al., 1998). According to
the genomic sequence, G14ext/G14 localize in the
intron following the exon encoding SRCR5 (Figure
1b). The deletion(s) therefore seem to occur most
often in the region that harbours the SRCR domain
and SID encoding exons.
The DMBT1 gene is built up by multiple locus specific
repeats
The repetitive structure of the protein is reflected by
the uniformly repeating exon – intron structure in the
region that codes for the SRCR domains and SIDs.
During the process of sequencing it became evident
that the homologies do also extend into the intronic
sequences. A crosswise comparison between the
dierent parts of the genomic sequence allowed the
identification of three major types of repeats to which
we will refer to as DMBT1-repeats (DMBT1reps).
The first group localizes in the 5’ region of the gene
and comprises four repeating units that each consists of
one of the exons encoding the carboxy-terminal part of
the 69 amino acid motif downstream of the leader
peptide and the preceding intronic sequence
(DMBT1rep1 – 1 to 1 – 4 in Figure 1b). These units
are about 1.4 kb in length, except for DMBT1rep1 – 2
that lacks 0.7 kb of the 3’ sequence. DMBT1rep1 – 1 to
1 – 4 share a 85.6 – 92.8% homology. The second group
comprises the genomic segments that extend from the
beginning of one SRCR exon to immediately before
the next SRCR exon (DMBT1rep2 – 1 to 2 – 13).
DMBT1rep2 – 1 to 2 – 13 are 74.6 – 99.8% identical
and can further be subdivided according to the
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deletions/insertions in the introns (Figure 4). Only the
intron following SRCR1 displays a major divergence.
DMBT1rep2 – 13 is incomplete because SRCR13 is
followed by the threonine rich domain and not by a
SID. The high similarity between the repeating units is
also reflected by the multiple hybridization sites of the
intronic probe DMBT1/59m21 (Figures 1a and 2b).
DMBT1rep2 – 9 to 2 – 11 show the highest level of
homology with 95.9 to 99.8% identity over a stretch of
4.1 kb. The third group of repeats is defined by
DMBT1rep2 – 2 and 2 – 3 that comprise a larger unit
repeated as DMBT1rep2 – 6 and 2 – 7 (DMBT1rep3 – 1
and 3 – 2, respectively in Figure 1b). DMBT1rep3 – 1
and 3 – 2 flank the most frequently deleted STSs
G14ext/G14.
Discussion
Lack of DMBT1 expression has been reported for
brain tumours and for oesophageal, gastric, colon,
and dierent types of lung cancer (Mollenhauer et al.,
1997; Mori et al., 1999; Wu et al., 1999). Somerville et
al. (1998) have observed deletions of the STS 74k in
4/21 GBM. Since the STS 74k localizes in the
prospective promotor region of DMBT1, one of the
possible explanations for the lack of expression is, that
in a subset of tumours, alterations of elements occur
that regulate the transcription of the gene. However,
before a correlation can be established, the expression
status of DMBT1 has to be determined in tumours
with a deletion of STS 74k. Other tumours without
DMBT1 expression may harbour more subtle changes
in the 5’ region. Since our genomic sequence extends
several kb into the 5’ region of the gene, testing of
this hypothesis becomes feasible now. In addition, the
availability of the 5’ sequence provides a basis for
studies of the transcriptional regulation of the gene.
LOH studies have revealed the interval between the
markers D10S209 and D10S587 as one of the possible
regions for a tumour suppressor gene at chromo-
some 10q in prostate cancer, small cell lung cancer
(SCLC), and endometrial carcinomas (Komiya et al.,
1996; Kim et al., 1998; Nagase et al., 1996). Frequent
losses of these two DMBT1 flanking markers have
been observed for D10S587 with 47% of the
endometrial carcinomas and for D10S209 with 86%
of the SCLC showing LOH (Nagase et al., 1996; Kim
et al., 1998). However, D10S209 and D10S587 are,
according to our initial mapping, several cM apart
from the DMBT1 gene (Mollenhauer et al., 1997). The
genomic sequence allowed the assignment of the
marker D10S1421 to the close vicinity of DMBT1 so
that the DMBT1 locus can now be addressed directly
in future LOH studies.
By extending the sequencing eorts beyond the
presumably last exon (exon 54), we identified an
additional putative exon with coding potential for a
transmembrane domain. The hypothetical TMD exon
of DMBT1 was identified by virtue of its homology to
the corresponding coding regions in the cDNAs of
CRP-ductin and Ebnerin. For CRP-ductin, it had been
demonstrated that alternative splicing gives rise to the
secreted and transmembrane form, respectively,
whereas it is unknown whether a similar mechanism
does account for the dierent isoforms of Ebnerin
(Cheng et al., 1996; Li and Snyder, 1995). Our findings
raise the possibility that an alternative splice form of
DMBT1 can be generated that may act as a
transmembrane receptor. This additional relationship
between DMBT1, CRP-ductin and Ebnerin indicates
that they may represent homologous genes in the three
species. We have identified CRP-ductin as the closest
relative of DMBT1 in mice, lending further support for
this hypothesis (Nollenhaver et al., unpublished).
By comparison of the exon utilization in the
formerly described DMBT1/6 kb.1 (Mollenhauer et
al., 1997) and the newly sequenced DMBT1/8 kb.1,
we found that alternative splicing gives rise to proteins
with dierent numbers of SRCR domains and SIDs.
Similar findings have been reported for the SRCR
proteins WC1/T19 and CD163/M130. WC1/T19 shows
dierential utilization of SRCR domains on dierent T
cell populations (O’Keee et al., 1999). In CD163/
M130 the introduction of a 99 bp sequence between
SRCR5 and SRCR6 gives rise to an isoform that is, in
contrast to other variants, insensitive to glucocorticoid
stimulation (Ho¨gger et al., 1998).
To date the only function that has been demon-
strated for SRCR domains is the binding of protein
ligands. In CD6, the membrane proximal SRCR
domain mediates the interaction with the ALCAM
receptor on activated lymphocytes (Whitney et al.,
1995). Therefore, one possibility is that the alternative
utilization of the SRCR domains in DMBT1 alters the
ligand binding properties of the protein. Although the
determination of the full spectrum of DMBT1 variants
has to await the characterization of further transcripts,
the lack of exon 14 (SID3a) and exon 17 (SID4b) in
DMBT1/8 kb.1 indicates that even the utilization of
the small exons encoding the SIDs may be dierentially
regulated. The characterization of a DMBT1 variant
virtually identical to DMBT1/8 kb.1 except for the
presence/absence of SID3a supports this hypothesis
(Holmskov et al., 1999). The studies of Ho¨gger et al.
(1998) have demonstrated that variants of CD163/
M130 with the positional analogue of a SID are
Figure 4 Relationships between the type 2 DMBT1 repeats.
SRCR domain encoding exons are drawn as red boxes, SID
encoding exons as orange boxes. Grey boxes are intronic
sequences homologous between at least two of the repeats,
yellow boxes depict the intronic sequences that are unique to
DMBT1rep2 – 1. Overlapping areas represent the regions of
homology. The dierent repeats are primarily subdivided
according to the deletions/insertions in the introns (indicated as
gaps/insertions). Values in brackets are the mean homology
between the repeats at the nucleotide level in per cent. Values at
the right are the identity of the respective repeat to the most
closely related member of the subgroup in per cent. According to
this classification, it can be dierentiated between five subgroups
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subjected to distinct regulatory mechanisms. Taken
together, these observations imply that alternative
splicing of the SRCR domain and SID encoding
exons may give rise to DMBT1 isoforms with different
functional properties.
The availabilty of the genomic structure allowed us
to determine the precise positions of the STSs that
initially have been used for mapping and deletion
analyses of the gene (Mollenhauer et al., 1997;
Somerville et al., 1998; Mori et al., 1999; Wu et al.,
1999). Although the number of tumours that have been
investigated for all STSs is still small and a more
systematic evaluation would be required, the current
data suggest that the STSs G14ext/G14 display the
highest tendency to be deleted. It is likely that these
deletions at least involve the region around the exon
coding for SRCR5. Hence, the minimum eect
expected to result from these deletions is the removal
of one or more of the alternatively spliced exons. The
data presented here provide the tools for the definition
of the borderlines of the deletions and thus for gaining
more insight into the molecular consequences of these
aberrations.
The presence of locus specific repeats in the DMBT1
gene is reminiscent of the configuration found for other
regions of chromosomal instability, as the Charcot-
Marie-Tooth type 1A (CMT1A) or the Smith-Magenis-
Syndrome (SMS) regions at chromosome 17p11.2 – p12
(Pentao et al., 1992; Chen et al., 1997). Therefore, in
analogy to the 17p region, the DMBT1 repeats may
lead to an increased chromosomal instability. For
example, an intra- or interchromosomal recombination
between DMBT1rep3 – 1 and 3 – 2 is predicted to lead
to a loss of the intervening sequences including the
STSs G14ext/G14 and some of the alternatively spliced
exons.
Somerville et al. (1998) have described a GBM
case with an apparent discontinuous deletion. The
tumour showed a loss of the STSs G14ext and 60k
but retention of the intervening STS G14. The
CMT1A/SMS region at 17p also overlaps with a
breakpoint cluster region that is thought to be
involved in the formation of the isochromosome 17q
in primitive neuroectodermal tumours (Scheurlen et
al., 1997). One of the possible explanations for the
discontinuous deletion, as suggested by Somerville et
al (1998), is a more complex rearrangement that
may include a translocation with the breakpoint in
the vicinity of the DMBT1 gene. However, based on
the configuration at the DMBT1 locus, a provocative
alternative hypothesis would be that this GBM
belongs to a potentially existing subset of tumours
with a translocation breakpoint within the DMBT1
gene.
The complete sequence and the genomic organiza-
tion of the candidate tumour suppressor gene DMBT1
has been established with this report. Wu et al. (1999)
have investigated mutations of DMBT1 in lung
tumours by amplification and sequencing of over-
lapping cDNAs. However, this approach may cause
problems in the regions coding the highly homologous
SRCR domains and SIDs, because of the potential
presence of alternative splice products that may give
rise to mixed RT–PCR products of similar size. The
data presented here provide the basis for a detailed
investigation of mutations which will help to further
elucidate the role of DMBT1 as a potential tumour
suppressor.
Materials and methods
Genomic sequencing
To isolate clones that cover the gaps in the DMBT1 map, the
genomic Human Lambda PS library (MoBiTec) was
rescreened with the STS G14. The rescreen yielded another
11 G14 positive clones. The overlapping clones HLPS51 and
HLPS61 were found to cover the gaps and sequenced in
addition to the clones from the initial mapping (Mollenhauer
et al., 1997).
The genomic clones were sequenced by a combination of
primer walking and sequencing of PCR products generated
with primers located within the insert or with vector/insert
primers. For the clones covering the region with the locus-
specific repeats, a dierent strategy was applied. The clones
were digested to completion with the restriction enzymes RsaI
and MspI, respectively and partially digested with Sau3AI.
The digests were subcloned into the vector pBluescript,
transformed into E. coli, and transferred into microtitre
plates. Thirty randomly selected clones of each sublibrary
were sequenced with the vector primers T3 and T7 and
finished by primer walking. Coligations and other cloning
artefacts could be excluded by ascertaining an at least
twofold coverage with sequences derived from independent
sublibraries. The remaining gaps were closed by sequencing
of PCR products obtained from the genomic clones or the
subclones.
In addition, long range PCR products containing the
regions with the exons 30 – 32 and 33 – 35, respectively, were
generated, cloned into the pCR2.1 vector (Invitrogen) and
sequenced by primer walking to confirm the assembly in this
region. The long range PCR was carried out under the
following conditions: 50 ng genomic DNA as template,
20 pmol of each primer (gap2f2 5’-CCCTGATTGTTGTC-
CATGCC-3’ and 59a17r1 5’-GTGGGCAAAGTAGT-
CAAGTTTC-3’), 50 mM Tris-Cl pH 9.3, 16 mM (NH4)2SO4,
2 mM MgCl2, 100 mM each dNTP, 0.4 ml of a 18 : 2 (Taq : Pfu)
polymerase mix (Taq: 5 U/ml, Perkin Elmer; Pfu: 2 U/ml,
Stratagene) in a final volume of 50 ml. After an initial
denaturation for 3 min at 948C, 40 cycles with 1 min 948C,
1 min 608C, and 6 min 728C were carried out followed by an
extension for 10 min at 728C.
DNA sequencing was carried out by using dye terminator
chemistry (Amersham) and sequencing reactions were
processed with automated DNA sequencers (Applied
Biosystems, model 373A/377). Sequences were assembled
with the support of the GAP4 program of the Staden
package.
Sequence analyses
Exon-intron boundaries were determined by comparison of
the genomic sequence with the formerly sequenced DMBT1/
6 kb.1 cDNA (EMBL Accession no. AJ000342). Recognition
sites for restriction enzymes were identified with the program
MAPSORT of the GCG package. Sequence homologies were
determined with the programs BESTFIT and FASTA and
potential N-glycosylation sites were identified with the
program PROSITE (all programs of the GCG package).
Southern blotting
Thirty mg genomic DNA from peripheral blood leukocytes of
eight normal individuals was digested for 2 h with 300 U
RsaI (Boehringer Mannheim). The digested DNA was
separated for 20 – 22 h on 1.2% agarose gels at 45 V,
transferred overnight with 0.4 M NaOH to Hybond N+
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membranes (Amersham), and neutralized with 26SSC. The
hybridization was carried out at 658C in 15 ml Church buer
as described earlier (Mollenhauer et al., 1997). Kodak X-
OMAT AR films were exposed for 6 – 18 h. The cDNA probe
DMBT1/sr1sid2 covers 998 bp of the DMBT1 cDNA and
includes a part of exon 1 and exons 2 – 12. The probe was
generated by PCR with 10 pg of the 5.6 kb cDNA clone
(Mollenhauer et al., 1997) that covers the SRCR encoding
region of DMBT1/8 kb.1 as template. The PCR conditions
were 16PCR buer (Perkin Elmer), 1.5 mM MgCl2, 200 mM
each dNTP, 2 U Taq-Polymerase (Perkin Elmer) and
20 pmol of each of the primers dmbt1expel1sph (5’-
GGGTGCATGCCAAGG ACTAC AGAC TACGC TTC3’)
and dmbt1expsid2rbgl (5’-ACTGAGATCTGGTCCTGCTG-
TTGATGC-3’) in a final volume of 50 ml. The cycling
conditions were 3 min 948C followed by 40 cycles consisting
of 1 min 948C, 2 min 558C and 2 min 728C. The intronic
probe DMBT1/59m21 is a 368 bp PCR product generated
with 10 pg of the genomic clone HLPS61 as template. The
PCR reaction was set up as described above. The primers
were dmbt159m21f3 (5’-GAGGAGGTCTGGAAATA-
GAGG-3’) and dmbt159m21r3 (5’-GCAGATCCTTCCAC-
TATTGCC-3’). After an initial denaturation for 3 min at
948C, 40 cycles followed consisting of 30 s 948C, 30 s 608C
and 3 min 728C. PCR products were purified with the Qiagen
PCR purification kit. Labelling was carried out with 50 ng
DNA by the standard random priming protocol using
[a-32P]dATP and [a-32P]dCTP (Amersham).
RT–PCR and sequencing of cDNA clones
The RT–PCR and the cloning of the PCR products was
carried out as described elsewhere (Mollenhauer et al., 1997).
A 5.6 kb cDNA clone presumably covering the center part of
the 8 kb transcript was completely sequenced using the nested
deletion technique (Nested deletion kit; Pharmacia Biotech).
The cDNA clone had a frameshift mutation in codon 536
and a nonsense mutation in codon 768 most probably due to
errors introduced by the Reverse Transcriptase or during the
PCR. The sequence was corrected by comparison with the
genomic exons.
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